Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.
Saved in:
| Title: | Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study. |
|---|---|
| Authors: | Venturini J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Baysal MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chakraborty A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ahnert JR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Beck J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kahle M; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vining DJ; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. atsimber@mdanderson.org. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2026 Apr 10; Vol. 10 (1). Date of Electronic Publication: 2026 Apr 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41963611 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Venturini+J%22">Venturini J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Baysal+MA%22">Baysal MA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Chakraborty+A%22">Chakraborty A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yap+TA%22">Yap TA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ahnert+JR%22">Ahnert JR</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Dumbrava+EE%22">Dumbrava EE</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Beck+J%22">Beck J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kahle+M%22">Kahle M</searchLink>; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Vining+DJ%22">Vining DJ</searchLink>; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. atsimber@mdanderson.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101708166%22">NPJ precision oncology</searchLink> [NPJ Precis Oncol] 2026 Apr 10; Vol. 10 (1). <i>Date of Electronic Publication: </i>2026 Apr 10. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Nature%22">Springer Nature </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101708166 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2397-768X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222397768X%22">2397768X </searchLink><i>NLM ISO Abbreviation: </i>NPJ Precis Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41963611 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41698-026-01404-2 Languages: – Code: eng Text: English Titles: – TitleFull: Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Venturini J – PersonEntity: Name: NameFull: Baysal MA – PersonEntity: Name: NameFull: Chakraborty A – PersonEntity: Name: NameFull: Yap TA – PersonEntity: Name: NameFull: Fu S – PersonEntity: Name: NameFull: Hong DS – PersonEntity: Name: NameFull: Piha-Paul SA – PersonEntity: Name: NameFull: Naing A – PersonEntity: Name: NameFull: Ahnert JR – PersonEntity: Name: NameFull: Dumbrava EE – PersonEntity: Name: NameFull: Beck J – PersonEntity: Name: NameFull: Liu Y – PersonEntity: Name: NameFull: Kahle M – PersonEntity: Name: NameFull: Vining DJ – PersonEntity: Name: NameFull: Meric-Bernstam F – PersonEntity: Name: NameFull: Tsimberidou AM IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 04 Text: 2026 Apr 10 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 2397-768X Numbering: – Type: volume Value: 10 – Type: issue Value: 1 Titles: – TitleFull: NPJ precision oncology Type: main |
| ResultId | 1 |